Overview

Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults
Phase:
Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Collaborator:
WAYCro
Treatments:
Clocortolone
Clocortolone pivalate
Fluocortolone